skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Welcome to your Pharma Intelligence advantage

business Intelligence sales forecasts pharma intelligence

Market intelligence

We’re the world’s leading provider of drug, device, company, clinical trial and market intelligence in the competitive pharma and medtech markets.

News and Analysis

News and insight

We provide unrivalled and daily-updated global insight, drawn from extensive authoritative data sets and enriched by human validation.

Data_and_analytics

Data and analytics

Our premium quality data is drawn from 42,000 companies, 248,000 clinical trials in 175 countries and 65,000 drugs for 1,400 diseases.

consultancies pharma intelligence

Consultancy

Our bespoke clinical, commercial and market access solutions are designed to help you make smarter decisions that bring a better return on investment.

Global industry experts

Global industry experts

Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.

Trusted partnerships

Trusted partnerships

We’re the trusted partner of more than 3,000 companies including the top 50 pharma firms and top 10 contract research organizations.

ask the analyst pharma intelligence

Gold-standard service

Our customer services team will support you every step of the way so that our insight, intelligence and bespoke solutions match your needs.

Solution to suit needs

Tailor-made solutions

From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round your exact needs.

Our Specialties

Clinical trial intelligence

Clinical trial intelligence

Gain a competitive edge with comprehensive clinical trial intelligence. Find out what competitors are doing in key areas, understand regulations, view clinical trial and program timelines, identify sites and investigators. 
Read More
competitive market intelligence

Competitive and market intelligence

See the entire global biopharma and medtech market landscape in one place – our expert analysis and trusted databases cover all sectors of the industry.
Read More
business development licensing pharma intelligence

Business development and licensing

Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.

 

Read More
business portfolio strategy pharma intelligence

Pharmaceutical portfolio strategy

​Identify M&A targets and partnership opportunities, and develop business cases with our real-time intelligence, tools and analysis.
Read More
regulatory approval pharma intelligence

Regulatory approval

​An increasingly complex regulatory framework for the pharmaceutical, biotech and medtech industries presents growing challenges to businesses. We’ll help you stay ahead.
Read More
medtech competitive intelligence pharma intelligence

Medtech market intelligence

To succeed in medtech, you need to have your finger on the pulse – we’ll help you access the accurate, reliable information you need.
Read More
View more
View Less

Our trusted Pharma Intelligence brands

Biomedtracker
DMHC
In Vivo
Meddevicetracker
Medtech-Insight
Medtrack
Pharma consulting
Pharmaprojects
Pharmapremia
Pink Sheet
RxScorecard
Scrip
Sitetrove
Trialtrove

Pharma Intelligence latest insights

  • Biomedtracker

    Clinical Trials Industry Report

    By KNect365 17 Aug 2018

    Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.

    Topic Clinical trials Clinical trial optimization

    Single report

  • Pharma Consulting

    Changing the future of data

    17 Aug 2018

    With fewer successful drug launches in the market and expiring patents, competitive intelligence and commercial R&D decision makers are hard-pressed to make sound forecasting and planning decisions based on highly reliable data analysis. That’s a big challenge because, even with access to big data from many sources, the tasks associated with collecting, organizing and mapping data sets is time-consuming, costly and labour-intensive. As result, decision making takes longer and innovation suffers.

    Topic Business strategies Company analysis

    View white paper

  • Scrip

    Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT

    By Jessica Merrill 17 Aug 2018

    FDA approved Galafold under accelerated approval, paving the way for the launch of the first oral therapy to treat a subset of patients with the rare condition Fabry disease. Amicus priced Galafold at $315,000 per year.

    Topic FDA

    View article

  • Scrip

    Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability

    By Sten Stovall 17 Aug 2018

    Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.

    Topic Research Business strategies

    View article

  • Medtech Insight

    QSR Author Kim Trautman Predicts What A Mash-Up Of FDA's Quality System Regulation And ISO 13485 Might Look Like

    By Shawn M. Schmitt 17 Aug 2018

    US FDA will face high hurdles as it works to write a new rule that would merge the agency's Quality System Regulation with international quality systems standard ISO 13485. That's according to Kim Trautman, a longtime industry insider who wrote the QSR in the early to mid-1990s. "It’s a clear heavy lift from a regulatory policy perspective" that could take as long as five years to complete, she says. In the meantime, Trautman offers some insight into what device-makers might see in a new hybrid quality systems regulation from FDA. She addresses everything from corrective and preventive action (CAPA) to labeling, and complaint handling to risk management – and more.

    Topic FDA

    View article

  • Medtech Insight

    Pre-Certs, Test Groups And More: US FDA Outlines Possible New Dx Paradigm

    By Sue Darcey 17 Aug 2018

    The agency has responded to a draft diagnostics reform bill in Congress with proposed reforms that diverge some ways from the proposed legislation, but stick with the underlying goal of completely remaking how lab tests, including test kits and lab-developed tests, are regulated. The agency has put forward a proposal to establish a pre-certification process for test developers, divide most tests into high- or low-risk categories (but exempt many from pre-market review) and remove the concept of substantial equivalence.

    Topic FDA

    View article

  • Rose Sheet

    GC3 Announces Preservative Challenge Winners

    By Ryan Nelson 17 Aug 2018

    Avisco, a biotech startup focused on the antimicrobial properties of the Inula viscosa plant, and IMD Natural Solutions, whose INS Glycolipid mushroom extract purportedly is “up to 80 times more effective than traditional preservatives,” are among winners named Aug. 6 by GC3.

    Topic BioPharmaceutical

    View article

  • In Vivo

    True Innovation In Women's Health Hindered Because Conditions Are Not Fatal

    By Lucie Ellis 17 Aug 2018

    Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.

    Topic Drug approval Drug review

    View article

  • Biomedtracker

    Biomedtracker 2018 Early Outlook Report

    15 Aug 2018

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topic Drug development landscape

    Single report

  • Biomedtracker

    Biomedtracker Q3 2018 Outlook Report Extract

    15 Aug 2018

    Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter. 

    Topic Drug development landscape

    Single report

  • Meddevicetracker

    Meddevicetracker Q3 2018 Outlook Report Extract

    14 Aug 2018

    In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology,  and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.

    Single report

  • Scrip

    Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

    By Mandy Jackson 14 Aug 2018

    Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.

    Topic Business strategies Drug approval

    View article

  • Scrip

    A Safe Harbor For Biotechs Ascletis BeiGene Mark Early Wins For HK Exchange

    By Jules Quartly 14 Aug 2018

    The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.

    Topic Business strategies Company analysis

    View article

  • Pink Sheet

    US FDA’s Breakthrough And RMAT Designations: A Quick Guide

    By Bridget Silverman 14 Aug 2018

    Differences in eligibility and evidentiary criteria between the US FDA's two expedited regulatory programs are reflected in a new guide; metrics to date suggest comparable success rates for designation requests under the two programs. Our infographics aid in understanding the programs.

    Topic FDA

    View article

  • In Vivo

    Cancer's New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?

    By William Looney 13 Aug 2018

    The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.

    Topic Cancer

    View article

Featured products

pdpimage

Trialtrove: gold standard clinical trials intelligence

Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.

Key benefits:

  • Curated by experts
  • Clinical trial landscape view
  • Standard of care insights
More
pdpimage

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions
More
pdp image

Scrip: industry news and insights

Key benefits:

  • Follow market developments
  • Go beyond the news
  • Hear from news makers
More

Upcoming events

26 Aug 2018 , 09:30 CST

Switzerland

Industry conference

AMEE

Register

05 Sep 2018

Massachusetts , USA

Industry conference

BioPharm America 2018

Register

06 Sep 2018

Industry conference

IMAC 2018

Register
View All Events

Keep up to date

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now